TB-500

TB-500 is a synthetic fragment corresponding to an active region of thymosin beta-4, a naturally-occurring 43-amino-acid protein that plays roles in cell migration and actin binding. The fragment is studied primarily in animal-model recovery research.

Mechanism

• Actin binding. The fragment retains the actin-binding site of the parent protein, relevant to cytoskeletal remodeling during cell migration.
• Cell migration. Studied for its role in mobilizing progenitor cells to sites of tissue injury.
• Angiogenesis. Parallel literature to BPC-157 on new blood-vessel formation at injury sites.

Common research protocols

Dosing information below reflects published research literature. It is not medical advice and is not a treatment plan.

• Common research window. 4-6 week loading phase, then reduced maintenance dosing.
• Route. Subcutaneous injection.
• Frequently paired with. BPC-157 — the two are commonly co-administered in the recovery literature.

Evidence at a glance

• Animal models. Studied in cardiac, dermal, and skeletal-muscle injury models.
• Human data. Small studies and case reports. No completed Phase 3 for a general recovery indication.
• Unknowns. Long-term human safety, pharmacokinetics in humans.

Reconstitution & handling

Lyophilized peptides ship as freeze-dried powder. Reconstitute with bacteriostatic water; refrigerate the reconstituted vial. Use the reconstitution calculator to get syringe-unit readings for your target dose. General reconstitution and syringe guidance in the How It Works page.

Primary-literature list for this guide available on request via contact.